Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5615_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •PEGylated Nanocarriers in Medicine and Pharmacy
- •Preface
- •Contents
- •Editors and Contributors
- •About the Editors
- •Contributors
- •1.1.3.1 Passive Targeting Agent
- •1.1.3.2 Solubility Enhancers
- •1. PEGylated Pharmaceutical Nanocarriers
- •1.1 PEGylation
- •1.1.1 PEG Characteristics
- •1.2 PEGylation Determination
- •1.2.2.1 Thermal Gravimetric Analysis (TGA)
- •1.2.2.2 Nuclear Magnetic Resonance (NMR)
- •1.2.2.4 X-Ray Photoelectron Spectroscopy
- •1.3.1 Nanoparticulate System
- •1.3.1.1 Solid Lipid Nanoparticles
- •1.3.1.2 Nanostructured Lipid Carriers (NLCs)
- •1.3.1.3 Polymeric Nanoparticles
- •1.3.2 Metal Nanoparticles
- •1.3.2.1 Silver Nanoparticles
- •1.3.2.2 Gold Nanoparticles
- •1.3.2.3 Titanium Dioxide Nanoparticles
- •1.3.2.4 Copper Nanoparticles
- •1.3.3 Vesicular Systems
- •1.3.3.1 Liposomes
- •1.3.3.2 Niosomes
- •1.3.3.3 Ethosomes
- •1.4.1 Cancer
- •1.4.2 Gene Delivery
- •1.4.3 Diagnostics Imaging
- •1.4.4 Vaccines
- •1.4.5 Rheumatoid Arthritis
- •1.4.6 Hemophilia
- •1.4.7 Pain Therapy
- •1.4.8 Diabetes
- •1.4.9 Others
- •1.6 Conclusion
- •References
- •2.1 Introduction
- •Nanoprecipitation (Solvent Diffusion)
- •Emulsification (Solvent Evaporation or Nanoemulsion)
- •Physical Adsorption Strategy
- •2.2.2.1 Pre-Insertion PEGylation
- •2.2.2.2 Post-Insertion PEGylation
- •2.3.1 Indirect Assessment (Qualitative Assessment)
- •2.3.1.1 Particle Size
- •2.3.1.2 Zeta Potential
- •2.3.1.3 Surface Hydrophilicity
- •2.3.1.4 Microscopic Techniques
- •2.3.1.5 Fourier Transform-Infrared Spectroscopy (FT-IR)
- •2.3.2 Direct Assessment (Quantitative Assessment)
- •2.3.2.1 Colorimetric Methods
- •2.3.2.2 Chromatographic Methods
- •2.3.2.4 Nuclear Magnetic Resonance (NMR)
- •2.3.2.5 X-Ray Photoelectron Spectroscopy (XPS)
- •References
- •3.1 Introduction
- •3.2 Characterization Techniques
- •3.3 Infrared Spectroscopy
- •3.4 Raman Spectroscopy
- •3.5 X-Ray Photoelectron Spectroscopy
- •3.6 Nuclear Magnetic Resonance
- •3.7 Energy-Dispersive X-Ray Spectroscopy
- •3.8 Mass Spectroscopy (MS)
- •3.9 Thermogravimetric Analysis
- •3.10 Differential Scanning Calorimetry
- •3.11 Atomic Force Microscopy
- •3.12 Scanning Electron Microscopy
- •3.13 Transmission Electron Microscopy
- •3.14 Conclusion
- •References
- •4.1 Introduction
- •4.3.1 Nanoparticles PEGylation
- •4.3.2 Polyplexes (PP) PEGylation
- •4.5.1 Systemic Drug Delivery
- •4.5.2 Nonsystemic Drug Delivery
- •4.5.2.3 PEGylated Intravaginal Nanocarriers
- •4.5.2.6 Vaccines Entrapped PEGylated Nanocarriers
- •4.6.2 PEG Molecular Weight (MW)
- •4.7 PEGylated Nanocarriers Products
- •4.8.3 Disadvantageous Physicochemical Properties
- •4.8.5 Limited RES Evasion Capacity
- •4.9 Conclusion
- •References
- •5.1 Introduction
- •5.1.2 PEG Solubility Characteristics
- •5.2 Water-Soluble PEGylated Small Molecule Drugs
- •5.3 Soluble PEGylated Proteins/Enzymes
- •5.3.2 Organic Solvent–Soluble PEGylated Proteins/Enzymes
- •5.4 Water-Soluble PEGylated Drug Nanocarriers
- •5.4.1 Water-Soluble PEGylated Silicon Nanocarriers
- •5.4.2 Water-Soluble PEGylated Carbon Nanotubes
- •5.4.4 Water-Soluble PEGylated Dendrimers
- •5.4.5 Water-Soluble PEGylated Polymeric Micelles
- •5.5 Hydrated or Hydrophilic PEGylated Drug Nanocarriers
- •5.5.1 Hydrated PEGylated Lipid Nanocarriers
- •5.5.2 Hydrophilic PEG-Coated Zein Nanocarriers
- •References
- •5.6.4.1 PEG Chain Length/Molecular Weight
- •6.1 Introduction
- •Increased Solubility
- •Improved Stability
- •Reduced Immunogenicity
- •Enhanced Circulation Time
- •Heterogeneity
- •6.3.1 Enhancing Immune Responses
- •6.3.2 Suppressing Immune Responses
- •6.3.3 Immune Evasion
- •6.4.1 Strategies to Overcome Immunological Barriers
- •6.4.1.1 PEGylation
- •6.4.1.2 Cell Membranes
- •6.4.1.3 Carbohydrates
- •6.4.1.4 Proteins
- •6.6.1 Cancer Therapy
- •6.6.2 Gene Therapy
- •6.6.3 Immunotherapy
- •6.6.4 Central Nervous System (CNS) Drug Delivery
- •6.6.5 Pulmonary Drug Delivery
- •6.6.6 Ocular Drug Delivery
- •6.6.7 Cardiovascular (CVS) Drug Delivery
- •6.8 Conclusion
- •References
- •7.1 Introduction
- •7.3 Nanocarrier-Based Targeted Drug Delivery
- •7.4.1 Covalent Approach
- •7.4.2 Non-covalent Approach
- •7.4.2.1 PEGylation Via Monovalent Interactions
- •High-Affinity Host-Guest Interactions
- •7.4.2.2 PEGylation Via Multivalent Interactions
- •PEGylated Block Copolymers
- •PEGylated Graft Copolymers
- •Polyelectrolyte Complex-Based Systems
- •Non-ionic Interaction-Based Systems
- •PEGylated Dendritic Copolymers
- •PEGylated Copolymers Utilizing Mobile Side Groups
- •7.5 Various Targeting Strategies
- •7.5.1 Active Targeting
- •7.5.2 Passive Targeting
- •7.5.2.1 PEG Dilemma
- •7.7.1 Brain Disorders
- •7.7.2 Pulmonary Disorders
- •7.7.3 Cancer
- •7.7.4 Inflammatory Disorders
- •7.7.5 Bone Disorders
- •7.7.6 Blood Disorders
- •7.8 Stimuli-Sensitive Nanocarriers
- •7.8.1 External-Responsive Nanocarriers
- •7.8.1.1 Ultrasound-Responsive PEGylated Nanocarriers
- •7.8.1.2 Thermal-Responsive PEGylated Nanocarriers
- •7.8.1.3 Magnetic Responsive PEGylated Nanocarriers
- •7.8.2 Internal-Responsive Nanocarriers
- •7.8.2.1 pH-Responsive Systems
- •7.8.2.2 Redox-Responsive Systems
- •7.8.2.3 Enzyme-Responsive Systems
- •7.8.2.4 Hypoxia-Responsive Systems
- •7.8.3 Multimodal Responsive Nanocarriers
- •7.9 Conclusion
- •References
- •8.1 Introduction
- •8.3.1 PEGylated Liposome
- •8.3.2 PEGylated Micelles
- •8.3.3 PEGylated Nanogels
- •8.3.4 PEGylated Inorganic Nanoparticles
- •8.3.5 PEGylated Polymeric Nanoparticles
- •8.4.1 Cancer
- •8.4.1.1 Breast Cancer
- •8.4.1.2 Lung Cancer
- •8.4.1.3 Colon Cancer
- •8.4.1.4 Brain Cancer
- •8.4.2 Autoimmune Diseases
- •8.4.3 Inflammatory Disorders
- •8.4.4 Cardiovascular Diseases
- •8.4.5 Ocular Diseases
- •8.5 Conclusion
- •References
- •9.1 Introduction
- •9.4.1.1 Amino Acid Modifications
- •9.4.1.3 Cysteine Thiol Residue Conjugation
- •9.4.2 Releasable PEGs
- •9.7.1.1 Cationic Lipid Toxicology
- •9.8 RNA Lipid Nanoparticle
- •9.13 Conclusion
- •References
- •10.2.1 PEGylated Nanocarriers
- •10.2.1.1 Polymeric NPs
- •10.2.1.2 Liposomes
- •10.2.1.3 Dendrimers
- •10.2.1.4 Polymeric Micelles
- •10.6 Conclusion
- •References
- •11.1 Introduction
- •11.1.2 Factors Influencing PPDs’ Short-Term Efficiency
- •11.2 What Is PEGylation?
- •11.3.1 Random PEGylation
- •11.3.2 Site-Specific PEGylation
- •11.3.2.1 Amine Conjugation
- •11.3.2.2 Cysteine Conjugation
- •11.4.1 Binding Affinity
- •11.4.2 Altered Biological Activity
- •11.4.3 Physicochemical Modifications
- •11.4.4 PEG Size
- •11.4.5 PEG Structure
- •11.6 PK Profiling
- •11.9 FDA-Approved PEGylated Products
- •11.11 Conclusion
- •References
- •12.1 Introduction
- •12.1.2 Current Market Scenario
- •12.2.1 PEGylated Iron Oxide Nanoparticles
- •References
- •13.1 Introduction
- •13.2.1 PEGylated Lipid-Based NPs
- •13.2.2 PEGylated Polymeric Nanoparticles
- •13.2.3 PEGylated Metal-Based Nanoparticles
- •13.2.4 Multifunctional PEGylated Nanocarriers
- •13.2.5 Targeted PEGylated Nanocarriers
- •13.3.1 Surface Modification Chemistry
- •13.3.2 Polymer Chemistry
- •13.3.4 Characterization Techniques
- •13.4.1 Longer Circulation Time
- •13.4.2 Enhanced Cellular Uptake
- •13.4.3 Controlled Drug Release
- •13.5.1 Cancer Theragnostic
- •13.5.2 Cardiovascular Theragnostic
- •13.7.2 Prolonged Circulation Time
- •13.7.3 Improved Drug Delivery
- •13.7.4 Diagnostic Functionality
- •13.8 Technical Challenges
- •13.8.4 Limited Clinical Validation
- •13.10 Conclusion
- •References
- •14.1 Introduction
- •14.2 Reversible PEGylation Strategies
- •14.2.1 Reversible PEGylation Chemistry
- •14.2.2.1 Aromatic Linkers
- •14.2.2.2 Aliphatic Linkers
- •14.2.3 Cleavage Linkers
- •14.2.3.1 Hydrolyzable Linkers
- •14.2.3.2 Enzymatically Cleavable Linkers
- •14.2.4 pH-Responsive PEGylation
- •14.2.4.1 Proteasome Inhibitor MG132
- •14.2.5 Temperature-Responsive PEGylation
- •14.2.6 Light-Responsive PEGylation
- •14.3.1 Analytical Techniques
- •Zeta Potential
- •Hydrophobic Interaction Chromatography (HIC)
- •Near Infrared (NIR) Spectroscopy
- •Fourier Transform-Infrared Spectroscopy (FT-IR)
- •13C-NMR
- •Mass Spectrometry
- •High-Performance Liquid Chromatography (HPLC)
- •Calorimetry
- •X-Ray Photoelectron Spectroscopy (XPS)
- •Nuclear Magnetic Resonance (NMR)
- •TGA-DSC
- •14.3.2.1 Protein Adsorption
- •14.3.2.2 Cellular Association
- •14.3.2.5 Bioactivity Assay
- •14.3.2.6 Enzyme-Linked Immunosorbent Assay (ELISA)
- •14.3.2.7 Sandwich ELISA
- •14.3.2.8 Anti-PEG ELISA
- •14.3.3.1 In Vivo Blood Circulation Half-Life
- •14.3.3.2 Radiolabeling
- •14.4.1 Therapeutic Applications
- •14.4.1.1 Anticancer Activity
- •14.4.1.2 Antibiotic Administration
- •14.4.1.3 Enzyme-Replacement Therapy
- •14.4.1.4 Red Blood Cell Substitution
- •14.4.1.5 Oxygen Toxicity Diseases
- •14.4.2 Pharmaceutical Applications
- •14.4.2.1 PEGylated Liposomes
- •14.4.2.2 PEGylated Proteins
- •14.4.2.3 Targeted Delivery
- •14.5.1 Design Complexity
- •14.5.3 Biological Environment Stability
- •14.5.4 Trigger Selection
- •14.5.5 Immunogenicity
- •14.5.6 Scale-up Difficulties
- •14.5.8 Cost
- •14.6 Conclusion
- •References
- •15. Stimuli-Responsive PEGylated Nanocarriers
- •15.1 Introduction
- •15.2 External Stimuli-Responsive Systems
- •15.2.1 Thermoresponsive Systems
- •15.2.2 Magnetically Responsive Systems
- •15.2.3 Ultrasound-Triggered Drug Delivery
- •15.2.4 Light-Triggered Drug Delivery
- •15.2.5 Electroresponsive Systems
- •15.3 Internal Stimuli-Responsive Systems
- •15.3.1 pH-Responsive Systems
- •15.3.2 Redox-Responsive Systems
- •15.3.3 Enzyme-Responsive Systems
- •15.3.4 Self-Regulated Systems
- •15.4.3 Multistimuli Responsive Systems
- •15.7 Conclusion
- •References
- •16.1 Introduction
- •16.3 PEGylated Products
- •16.3.1 PEGylated Liposomes
- •16.3.2 PEGylated G-CSF
- •16.3.3 PEGylated Proteins
- •16.3.4 PEGylated Nanoparticles
- •16.5.1 Poly(Zwitterions)
- •16.5.2 Poly(Glycerols)
- •16.5.3 Poly(Amino Acids)
- •16.5.4 Poly(Oxazolines)
- •16.5.6 Poly(Vinylpyrrolidones)
- •16.5.8 Polypeptides
- •16.5.9 Carbohydrate-Based Systems
- •16.5.10 Hydrophilic Polymers
- •16.5.11 Non-PEGylated Nanoparticles
- •16.6 Future Prospects
- •16.7 Conclusion
- •References

1 PEGylated Pharmaceutical Nanocarriers
Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, Szebeni J, Ishida T
(2019) PEGylated liposomes: immunological responses. Sci Technol Adv Mater 20(1):710–724
Mollé LM, Smyth CH, Yuen D, Johnston APR (2022) Nanoparticles for vaccine and gene
therapy: overcoming the barriers to nucleic acid delivery. Wiley Interdiscip Rev Nanomed
Nanobiotechnol 14(6):e1809
Nascimento ÍF, Guimarães ATB, Ribeiro F, de Lima Rodrigues AS, Estrela FN, da Luz TM,
Malafaia G (2021) Polyethylene glycol acute and sub-lethal toxicity in neotropical Physalaemus
cuvieri tadpoles (Anura, Leptodactylidae). Environ Pollut 283:117054
Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, Zaharoff DA
(2020) Localized Interleukin-12 for cancer immunotherapy. Front Immunol 11:575597
Nunes SS, de Oliveira Silva J, Fernandes RS, Miranda SEM, Leite EA, de Farias MA, Portugal
RV, Cassali GD, Townsend DM, Oliveira MC (2022) PEGylated versus non-PEGylated pH-
sensitive liposomes: new insights from a comparative antitumor activity study. Pharmaceutics
14(2):272
Okyere D, Manso RH, Tong X, Chen J (2022) Stability of polyethylene glycol-coated copper
nanoparticles and their optical properties. Coatings 12(6):776
Padín-González E, Lancaster P, Bottini M, Gasco P, Tran L, Fadeel B, Wilkins T, Monopoli MP
(2022) Understanding the role and impact of poly (ethylene glycol) (PEG) on nanoparticle
formulation: implications for COVID-19 vaccines. Front Bioeng Biotechnol 10:882363
Pandey M, Choudhury H, Gorain B, Tiong SQ, Wong GYS, Chan KX, They X, Chieu WS (2021)
Site-specic vesicular drug delivery system for skin cancer: a novel approach for targeting.
Gels 7(4):218
Pannuzzo M, Esposito S, Wu L-P, Key J, Aryal S, Celia C, Di Marzio L, Moghimi SM, Decuzzi
P (2020) Overcoming nanoparticle-mediated complement activation by surface PEG pairing.
Nano Lett 20(6):4312–4321
Park T, Lee S, Amatya R, Cheong H, Moon C, Kwak HD, Min KA, Shin MC (2020) ICG-
loaded pegylated BSA-silver nanoparticles for effective photothermal cancer therapy. Int J
Nanomedicine 15:5459–5471
Pasek-Allen JL, Wilharm RK, Bischof JC, Pierre VC (2023) NMR characterization of polyethyl-
ene glycol conjugates for nanoparticle functionalization. ACS Omega 8:4331–4336
Pham Le Khanh H, Nemes D, Rusznyák Á, Ujhelyi Z, Fehér P, Fenyvesi F, Váradi J, Vecsernyés M,
Bácskay I (2022) Comparative investigation of cellular effects of polyethylene glycol (PEG)
derivatives. Polymers (Basel) 14(2):279
Rabanel J-M, Adibnia V, Tehrani SF, Sanche S, Hildgen P, Banquy X, Ramassamy C (2019)
Nanoparticle heterogeneity: an emerging structural parameter inuencing particle fate in bio-
logical media? Nanoscale 11(2):383–406
Rinck PA (2019) Magnetic resonance in medicine: a critical introduction. BoD–Books on Demand,
Norderstedt
Roces CB, Port EC, Daskalakis NN, Watts JA, Aylott JW, Halbert GW, Perrie Y (2020) Rapid
scale-up and production of active-loaded PEGylated liposomes. Int J Pharm 586:119566
Rondon A, Mahri S, Morales F, Dumoulin M, Vanbever R (2021) Protein engineering strategies for
improved pharmacokinetics. Adv Funct Mater 31:2101633
Sadalage PS, Patil RV, Havaldar DV, Gavade SS, Santos AC, Pawar KD (2021) Optimally bio-
synthesized, PEGylated gold nanoparticles functionalized with quercetin and campto-
thecin enhance potential anti-inammatory, anti-cancer and anti-angiogenic activities. J
Nanobiotechnol 19(1):1–17
Saikh MAA (2021) Aqueous lm coating the current trend. J Drug Deliv Therapeut 11(4-S):212–224
Sanchez Armengol E, Unterweger A, Lafeur F (2022) PEGylated drug delivery systems in the
pharmaceutical eld: past, present and future perspective. Drug Dev Ind Pharm 48(4):129–139
Sánchez-Cid P, Jiménez-Rosado M, Romero A, Pérez-Puyana V (2022) Novel trends in hydrogel
development for biomedical applications: a review. Polymers (Basel) 14(15):3023
Saravanan A, Kumar PS, Karishma S, Vo D-VN, Jeevanantham S, Yaashikaa P, George CS
(2021) A review on biosynthesis of metal nanoparticles and its environmental applications.
Chemosphere 264:128580
27

28
Sebak AA (2018) Limitations of PEGylated nanocarriers: unfavourable physicochemical prop-
erties, biodistribution patterns and cellular and subcellular fates. Int J Appl Pharmaceut
10(5):6–12
Selli D, Motta S, Di Valentin C (2019) Impact of surface curvature, grafting density and solvent
type on the PEGylation of titanium dioxide nanoparticles. J Colloid Interface Sci 555:519–531
Shah Z, Nazir S, Mazhar K, Abbasi R, Samokhvalov IM (2019) PEGylated doped-and undoped-
TiO2 nanoparticles for photodynamic therapy of cancers. Photodiagnosis Photodyn Ther
27:173–183
Shahbazi R, Jafari-Gharabaghlou D, Mirjafary Z, Saeidian H, Zarghami N (2023) Design and
optimization various formulations of PEGylated niosomal nanoparticles loaded with phyto-
chemical agents: potential anti-cancer effects against human lung cancer cells. Pharmacol Rep
75:442–455
Siani P, Frigerio G, Donadoni E, Di Valentin C (2022) Molecular dynamics simulations of cRGD-
conjugated PEGylated TiO2 nanoparticles for targeted photodynamic therapy. J Colloid
Interface Sci 627:126–141
Simone EA (2008) Filamentous and spherical polymer nanocarriers for enzyme therapeutics.
University of Pennsylvania, Philadelphia, PA
Singh A, Neupane YR, Sha S, Mangla B, Kohli K (2020) PEGylated liposomes as an emerging
therapeutic platform for oral nanomedicine in cancer therapy: invitro and invivo assessment.
J Mol Liq 303:112649
Singhvi G, Rapalli VK, Nagpal S, Dubey SK, Saha RN (2020) Nanocarriers as potential targeted
drug delivery for cancer therapy. Springer, Cham, pp51–88
Teramura Y, Kuroyama K, Takai M (2016) Inuence of molecular weight of PEG chain on inter-
action between streptavidin and biotin–PEG-conjugated phospholipids studied with QCM-
D.Acta Biomater 30:135–143
Thakur S, Kesharwani P, Tekade RK, Jain NK (2015) Impact of pegylation on biopharmaceutical
properties of dendrimers. Polymer 59:67–92
Verma V, Kaushik D (2020) Mupirocin mounted copper nanoparticle offered augmented drug
delivery against resistant bacteria. Indian J Pharmaceut Educ Res 54:637–646
Walkowiak-Kulikowska J, Wolska J, Koroniak H (2020) Biopolymer membranes in fuel cell appli-
cations. In: Biopolymer membranes and lms. Elsevier, Amsterdam, pp423–476
Yadav D, Dewangan HK (2021) Pegylation: an important approach for novel drug delivery system.
J Biomater Sci Polym Ed 32(2):266–280
Yaqoob AA, Umar K, Ibrahim MNM (2020) Silver nanoparticles: various methods of synthesis,
size affecting factors and their potential applications—a review. Appl Nanosci 10:1369–1378
Yin IX, Zhang J, Zhao IS, Mei ML, Li Q, Chu CH (2020) The antibacterial mechanism of silver
nanoparticles and its application in dentistry. Int J Nanomedicine 15:2555–2562
Zaghmi A, Greschner AA, Mendez-Villuendas E, Liu JY, de Haan HW, Gauthier MA (2019)
Determination of the degree of PEGylation of protein bioconjugates using data from proton
nuclear magnetic resonance spectroscopy. Data Brief 25:104037
Zhang H, Wang W, Akinc M, Mallapragada S, Travesset A, Vaknin D (2017a) Assembling and
ordering polymer-grafted nanoparticles in three dimensions. Nanoscale 9(25):8710–8715
Zhang H, Wang W, Mallapragada S, Travesset A, Vaknin D (2017b) Macroscopic and tunable
nanoparticle superlattices. Nanoscale 9(1):164–171
Zhang Y, Wang P, Mao H, Zhang Y, Zheng L, Yu P, Guo Z, Li L, Jiang Q (2021) PEGylated gold
nanoparticles promote osteogenic differentiation in invitro and in vivo systems. Mater Des
197:109231
Zhang C, Xu C, Gao X, Yao Q (2022) Platinum-based drugs for cancer therapy and anti-tumor
strategies. Theranostics 12(5):2115
Zhao C, Ma Z, Zhu XX (2019) Rational design of thermoresponsive polymers in aqueous solu-
tions: a thermodynamics map. Prog Polym Sci 90:269–291
Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M,
Eder P, Silva AM (2020) Polymeric nanoparticles: production, characterization, toxicology and
ecotoxicology. Molecules 25(16):3731
P. Pingale et al.

Methods andProtocols fortheSynthesis
ofPEGylated Pharmaceutical
Nanocarriers
Ala’AdnanAli, RakeshKumarTekade,
andRandaS.H.Mansour
Abstract
This chapter focuses on topics related to synthesizing PEGylated nanocarriers and
their characterization. The types of poly(ethylene glycol) (PEG) derivatives and con-
formation in addition to PEGylation techniques are detailed. Moreover, the methods
employed for synthesizing PEGylated nanocarriers are categorized and discussed in
detail. The methods explained are classied into self-assembly from PEG-containing
molecules by either nanoprecipitation or emulsication and surface modication of
nanocarriers with PEG chain covalently and noncovalently. Indirect assessments of
surface PEGylation efciency using particle size, surface hydrophilicity, zeta poten-
tial, etc. are emphasized, in addition to other methods used for direct assessments,
including colorimetric methods, chromatographic quantication methods, UV and
uorescence spectroscopy, and more. Finally, alternative polymers to PEG are briey
illustrated, as well as the challenges of nanocarriers PEGylation.
2
Keywords
PEGylated nanocarriers · Nanoprecipitation · Zeta potential · Polymers · Solvent
evaporation · Solvent diffusion · Chemical conjugation · Physical adsorption ·
Mushroom conformation · Brush conformation
A. A. Ali (*)
Faculty of Pharmacy, University of Jordan, Amman, Jordan
R. K. Tekade
National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An
Institute of National Importance, Government of India, Department of Pharmaceuticals,
Ministry of Chemicals and Fertilizers, Palaj, Opp. Air force station, Gandhinagar,
Gujarat, India
R. S. H. Mansour
Faculty of Pharmacy, Zarqa University, Zarqa, Jordan
29

30
A. A. Ali et al.
Abbreviations
APTES Amino propyl triethoxy silane
APTMS Amino propyl trimethoxy silane
CDCl3 Deuterated chloroform
Chln Cholane
Chol Cholesterol
CMC Critical micelle concentration
D2O Deuterated water
DLS Dynamic light scattering
DMAP 4-Dimethylaminopyridin
DMSO Dimethyl sulfoxide
DSPE Distearoyl-sn-glycero-3-phosphoethanolamine
EDC N′-ethylcarbodiimide
ELSD Evaporative light scattering detector
FT-IR Fourier transform-infrared spectroscopy
G4-PAMAM Generation 4 poly(amidoamine)
HIC Hydrophobic interaction chromatography
HPLC High-pressure liquid chromatography
LC Liquid chromatography
mPEG Methoxy-poly(ethylene glycol)
MS Mass spectrometry
NA Nucleic acid
NHS N-hydroxysuccinimide
NMR Nuclear magnetic resonance
PCL Poly(ε-caprolactone)
PCS Photon correlation spectroscopy
PEG Poly(ethylene glycol)
PEI Poly(ethylene imine)
PEO-PPO-PEO Polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide
PGA Poly(glutamic acid)
PGs Poly(glycerols)
PHDCA Poly(hexadecyl cyanoacrylate)
PHEMA Poly(2-hydroxyethyl methacrylate)
PHPMA Poly(hydroxypropyl methacrylate)
PLA Poly(lactic acid)
PLGA Poly(lactide-co-glycolide)
PLL Poly(-lysine)
POX Poly(oxazolines)
PPG Poly(propylene glycol)
PSA Polysebacic acid
pSLN PEGylatec solid lipid nanoparticles
PVL Poly(δ-valerolactone)
PVP Poly(vinylpyrrolidone)
RH Hydrodynamic radius”

2 Methods andProtocols fortheSynthesis ofPEGylated Pharmaceutical Nanocarriers
31
RI Refractive index
SEM Scanning electronic microscopy
SLN Solid lipid nanoparticles
SM Sphingomyelin
TEA Triethanolamine
TEM Transmission electron microscopy
THF Tetrahydrofuran
UV Ultra-violet
XPS X-ray photoelectron spectroscopy
2.1 Introduction
Several hydrophilic polymers have been utilized to coat the surface of nanocarriers,
such as polysaccharides, polyacrylamide, poly(glycerols), poly(vinyl alcohol),
poly(oxazolines), poly(ethylene glycol) (PEG), and PEG-containing co-polymers.
Among all the polymers, PEG and PEG-copolymer are the most commonly used
and recognized as the gold standard. PEGylated nanocarriers have several advantages, such as avoidance of the nonspecic recognition by serum proteins, cells,
tissues, and organs, reducing toxicity, and extending circulation time (Moghimi and
Szebeni 2003; Vonarbourg etal. 2006).Therefore, PEGylated nanocarriers can be
considered valid new pharmaceutical entities compared with their non-PEGylated
counterparts.
PEGylation refers to attaching or coating the nanocarrier surface with PEG via
adsorption, grafting, or entrapment methods (Howard etal. 2008). In recent few
years, a considerable amount of research has been directed toward PEGylation
chemistry, allowing the researcher to improve the PEGylation strategies from a
“random” to a “site-specic” PEGylation. In addition, PEGylation is currently
focused on using bifunctional PEG chains, which react from one side with the particle surface and on the other side with a targeting agent.
The objectives of this chapter are to provide the readers with the methods and
protocols of PEGylation, the tools to assess PEG surface quantitatively and qualitatively, and the main alternative polymers to PEG.
2.1.1 Physical andChemical Properties ofPEG
PEG is a synthetic polymer of ethylene glycol (HO-CH2-CH2-OH) that is available
in different molecular weights ranging from hundreds to several thousands of
Daltons (Chen etal. 2005). PEGs have good water solubility that decreases with
increases in chain lengths(Sanchez Armengol etal. 2022). PEGs with low molecular weight (less than 800Daltons) are highly soluble in water and are liquids at room
temperature (Chen etal. 2005).

32
A. A. Ali et al.
Different useful features make PEG one of the most popular polymers for modifying nanocarriers. PEG is soluble in both water and many organic solvents due to
the presence of both hydrophilic and hydrophobic groups in its structure (Pasut and
Veronese 2012). Moreover, the PEG molecule has high exibility due to the absence
of a bulky substituent group on the PEG backbone (Mohapatra etal. 2019). Another
feature of PEG is its distinctive stability against decomposition by acids, bases,
moderately high temperatures, and hydrogen peroxide, oxidation, and reduction
(Chen etal. 2005). In addition, PEG can be functionalized by selectively oxidizing
the terminal OH group with various terminal end groups or by attaching large
ligands, such as biomolecules (Karakoti etal. 2011).
The synthesis of PEG (Fig.2.1) involves a condensation polymerization where
ethylene is reacted with aluminum oxide to obtain oxirane. Then, the polymerization of diethylene glycol as the starting molecule with oxirane takes place at 130°C
in the presence of alkaline catalysts, as it eliminates water, subsequently the reaction is terminated by adding an acid (Li and Kao 2003).
2.1.2 Uses ofPEG
PEG has been widely used in biomedical applications, especially in pharmaceutics, due to its high solubility in aqueous media, good tolerance, biocompatibility,
FDA- approved, and negligible interference with the drug release (Knop
etal. 2010).
A breakthrough in PEGylation was the modication of albumin and catalase by
Abuchowski in 1977, which decreased the immunogenicity of the proteins and
increased their circulating time in blood (Abuchowski et al. 1977). The rst
PEGylated nanocarrier introduced in 1995in the US market was Doxil®, a formulation of PEGylated liposomes of doxorubicin (Barenholz 2012). Later, various FDAapproved PEGylated products have emerged like cytokines (interferon-α2a and
interferon-α2b), enzymes (bovine adenosine deaminase, Lasparginase, and urate
oxidase), hormones (epoetin-β), antibodies and their fragments, other organic molecules (pegvisomant and pegatinib), and others are in clinical trials (Pasut and
Veronese 2009). In addition to enzymes and proteins, PEGylation has been widely
utilized in the modication of nanocarriers delivery systems, including polymeric
nanocarriers (Ebrahimnejad etal. 2011), liposomes (Allen etal. 1995), solid lipid
nanoparticles (SLN) (Yuan etal. 2013), and micelles (Lee etal. 2011). This results
in improving their invivo stability and solubility, increasing their accumulation at
the target site, and reducing their clearance rate from circulation (Torchilin 1998;
Maruyama 2002).
Fig. 2.1 Synthesis of PEG. ((Sanchez Armengol etal. 2022) with permission) . ©Copyright 2022.
Published by Informa UK Limited, trading as Taylor & Francis)

2 Methods andProtocols fortheSynthesis ofPEGylated Pharmaceutical Nanocarriers
33
2.1.3 Types ofPEG Derivatives
Diverse types of PEG derivatives with differences in shapes, functionality, and
molecular weights affect the option of a suitable PEG moiety for therapeutic applications (Mohapatra etal. 2019).
2.1.3.1 According totheShape ofthePolymer
According to the shape of the polymer, PEGs are classied into (Fig.2.2):
(a) Linear PEG derivatives: they are the simplest agents, having one reactive func-
tional group that aids in conjugation, and the other end is a methoxy group or a
targeting molecule to make the PEG monofunctional. Also, bifunctional PEGs
that have two functional groups (refers to Sect. 2.1.3.2) (Mohapatra etal. 2019).
(b) Y-shaped PEG derivatives: two linear PEG derivatives are linked to active
groups (Santos etal. 2018), they are characterized by higher invivo stability
against physiological conditions like pH, temperature, and enzymatic environment (Veronese etal. 1997).
(c) Forked PEG derivatives: they pose multi-proximal reactive groups at one or
both ends of a linear PEG chain (Veronese etal. 1997).
Fig. 2.2 Different-shaped PEGs. (a) Linear PEG. (b) Bifunctional PEG. (c) Y-shaped PEG. (d)
Multi-arm PEG. (e) Fork-shaped PEG; providing at one PEG chain end multi-proximal reactive
groups. (f) Fork-shaped PEG; providing at both PEG chains end multi-proximal reactive groups.
( ) represents functional groups of PEG derivatives

34
A. A. Ali et al.
(d) Multi-arm PEG derivatives: they are star-like structures with multi-hydroxyl or
functional groups. Thus, the number of active sites and molecular weight are
higher (Kim etal. 2016).
2.1.3.2 According toFunctionality
PEG functionalization of nanocarriers can enhance the targeting, controlling the
release of drugs from colloidal nanostructures (Howard etal. 2008), and increasing
the invivo circulation half-life (Steenpaß etal. 2006). The structure of PEG possesses two equivalent hydroxyl groups in which a variety of reactive functional
groups or bioactive species can be attached by covalent coupling (Gajbhiye
etal. 2007).
According to functionality, PEGs are classied into monofunctional PEGs and
bifunctional PEGs. In monofunctional PEGs, one of the hydroxyl groups is replaced
with a reactive functional group (Turecek etal. 2016). Examples of those functional
groups are bromo, amino, carboxymethyl, succinimido succinate, tosylate, mesylate, aldehyde, octadesylamine, monopalmitate, stearyl oxy, or methoxy (Harris 1985).
To illustrate, Steenpa etal. prepared monofunctional soy sterol-PEG1300 ethers
by attaching a tresyl group to the end of the PEG chain. Then the PEG chain was
attached to bovine serum albumin, and the sterol–PEG–protein formed was inserted
into the outer liposome monolayer using the post-insertion method. This resulted in
an increasing invivo circulation half-life of those particles (Steenpaß etal. 2006).
On the other hand, bifunctional PEGs have two reactive functional groups. They
are usually used for cross-linking and conjugation of drugs, targeting ligands, dyes,
and proteins.
Bifunctional PEGs could be homo-biofunctionalized or heterobifunctional. The
homo-functionalized PEGs contain two similar functional groups, and the heterobifunctional PEGs include two different groups. An example of a linear heterobifunctional PEG is thiol-PEG-coumarin for functionalizing gold nanoparticle surfaces
(Fig.2.3) (Fu etal. 2004).
2.1.4 PEG Conformations ontheNanocarrier Surface
PEG forms a exible layer on the surface of nanocarriers (Heald etal. 2002), blocking the adsorption of opsonins (proteins) by steric hindrance (Drobek etal. 2005)
and their consequent uptake by phagocytic cells (Storm etal. 1995). The PEG-chain
Fig. 2.3 Schematic representation of the functionalization of gold nanocarrier with coumarin
PEG-thiol. ((Fu etal. 2004) with permission)

2 Methods andProtocols fortheSynthesis ofPEGylated Pharmaceutical Nanocarriers
35
conformation on the particle surface is often described as a mushroom or a brush
model (Amoozgar and Yeo 2012).
When the surface PEG density is low, it results in the mushroom state conguration. As the PEG density increases, it results in the brush state conguration (Tirosh
etal. 1998) as in Fig.2.4.
The “mushroom” conguration has meager surface coverage, leading to large
areas for protein binding. On the contrary, the “brush” conguration is characterized by a very high surface coverage, which provides a higher anti-opsonization
effect resulting in more effective binding, prolonging the circulation time of nanocarriers compared to the former (Photos etal. 2003).
The optimal PEG density varies by system. For example, for poly(lactic acid)
(PLA) nanocarriers (Sheng etal. 2009) or poly(lactide-co-glycolide) (PLGA) nanocarriers 10wt.% PEG density was reported as optimal regarding particle dispersibility and stealth effect (Beletsi etal. 2005). However, Gref etal. considered that
the optimal PEG surface density for PLA, PLGA, and polycaprolactone nanocarriers was 5wt.% and that any further increase in the levels of PEG content will not
result in further reduction in protein adsorption (Gref etal. 2000).
In liposomes, a mushroom-like shape is obtained using <5% PEG, mushroom- or
brush-like shape is obtained using 5–15% PEG, while >15% PEG gives a brush-like
shape. Hence, the higher the molar PEG–lipid/lipid composition ratio, the higher
the surface density (Nosova etal. 2019).
2.1.5 Types ofPEGylation Techniques
The key step of PEGylation is a conjugation of the PEG chains by different spacers
or linkers with nanocarriers like polymeric nanocarriers, micelles, liposomes, or
inorganic nanocarriers. Numerous derivatives of PEG (i.e., linear PEG and Y-shaped
PEG) are used in the PEGylation techniques (Zacchigna etal. 2011; Chen et al.
2011). There are three types of PEGylation techniques: rst, second, and third
generations.
Fig. 2.4 PEG-chain conformations on the nanocarrier surface, ( ) represent PEG chains

36
In rst-generation PEGylation, linear and low molecular weight PEG is conjugated with a reactive group with hydroxyl groups like carbonates, chlorides, and
anhydrides (Damodaran and Fee 2010). This type of PEGylation results in nonspecic random conjugations and is inefcient for protein conjugation. In secondgeneration PEGylation, branched structured PEG derivatives are used, which are
more site-specic because more functional groups like esters, aldehydes, and
amides are available (Damodaran and Fee 2010). In addition, branched PEGylation
is more effective in diminishing immunogenicity and increasing the circulation
time than linear PEG.On the other hand, it might affect the biomolecules’ activities; therefore, the third generation is developed to conserve drug bioactivity
(Monfardini et al. 1995). In third-generation PEGylation branched, Y-shaped
structures revealed a reduction in viscosity and lack of organ accumulation
(Singh 2015).
A. A. Ali et al.
2.2 Methods andProtocols fortheSynthesis
ofPegylated Nanocarriers
Due to variations in the chemical makeup, the methods and protocols used for the
PEGylation of nanocarriers can be classied under polymeric nanocarriers, liposomes, micelles, and inorganic nanocarriers.
2.2.1 PEGylation ofPolymeric Nanocarriers
The chemistry of PEGylation of polymeric nanocarriers cannot be dened under
a single heading, as that of proteins, due to high variance in the availability of
functional groups and mode of preparation. PEGylation of a nanocarrier surface
can be achieved in different ways (Fig.2.5), including the preparation of nanocarriers by self-assembly with block co-polymers of PEG and hydrophobic
polymers (Gref etal. 1994). Otherwise, it can achieved by the addition of PEGs
on preformed nanocarriers by physical adsorption or chemical conjugation of
functional PEGs to the available surface reactive groups (Owens and
Peppas 2006).
The main drawback of physical adsorption methods is the risk of desorption, the
removal of the coating layer invivo, and consequent loss in pharmacokinetic outcomes that the polymer should provide (Neal etal. 1998). To overcome the desorption, PEGylated nanocarriers are prepared by self-assembly using a modied
derivative of polymers by choosing a proper method of nanoparticle preparation
(emulsication and precipitation) in which the hydrophobic portions of PEG chains
embedded inside the matrix of nanocarriers and hydrophilic portions orient toward
the aqueous phase (Yoncheva etal. 2005). However, this does not ensure that PEG
chains are localized only on the surface of nanocarriers, as PEGs may retain within
the particle core (Vila etal. 2004). Therefore, the chemical conjugation method for
PEGylation of nanocarriers’ surface is preferred.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
